Evidence map›Paper›PMID 35277756›Full record

ArticleEuropean journal of nutrition2022

Multidisciplinary lifestyle intervention is associated with improvements in liver damage and in surrogate scores of NAFLD and liver fibrosis in morbidly obese patients.

Monika Bischoff, Sebastian Zimny, Sebastian Feiner, Johannes Sauter, Svenja Sydor, Gerald Denk, Jutta M Nagel, Gert Bischoff, Christian Rust, Simon Hohenester

Registry-linked trialOpen access · hybridAbstract read
In one paragraph

Article in European journal of nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06121999 (13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06121999 nacompletednot on this mapstarted 2023, after this paper: background citation

13-Week Behavioral Lifestyle Intervention for Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-associated Steatosis (MASH) in Adults: A Randomized Control Trial

TypeinterventionalSponsorGrand Valley State UniversityRan2023 to 2024Enrolled24ConditionsMetabolic Associated-dysfunction Steatotic Liver Disease (MASLD), Metabolic Associated-dysfunction Steatohepatitis (MASH)ArmsStandard of care acceptance-based behavioral weight loss program, Occupational therapy dietary and lifestyle modifications
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Review
  3. Missing the Target: A Scoping Review of the Use of Percent Weight Loss for Obesity Management.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Monika BischoffKrankenhaus Barmherzige Brüder München, Romanstrasse 93, 80639, Munich, Germany.
Sebastian ZimnyDepartment of Medicine II, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Sebastian FeinerKrankenhaus Barmherzige Brüder München, Romanstrasse 93, 80639, Munich, Germany.
Johannes SauterDepartment of Medicine II, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Svenja SydorDepartment of Internal Medicine, University Hospital Knappschaftskrankenhaus, Ruhr-University Bochum, In der Schornau 23-25, 44892, Bochum, Germany.
Gerald DenkDepartment of Medicine II, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany.
Jutta M NagelKrankenhaus Barmherzige Brüder München, Romanstrasse 93, 80639, Munich, Germany.
Gert BischoffKrankenhaus Barmherzige Brüder München, Romanstrasse 93, 80639, Munich, Germany.
Christian RustKrankenhaus Barmherzige Brüder München, Romanstrasse 93, 80639, Munich, Germany.
Simon HohenesterDepartment of Medicine II, LMU Munich, Marchioninistrasse 15, 81377, Munich, Germany. simon.hohenester@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-9982-6317
Krankenhaus Barmherzige Brüder · DELMU Klinikum · DEUniversitätsklinikum Knappschaftskrankenhaus Bochum · DE

Funding

deutsche forschungsgemeinschaft HO4460/3-1
6 · The paper itself

Abstract

purposeNon-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. Particularly morbidly obese patients are at risk of developing progressive liver disease. Nutritional and lifestyle intervention is recommended as the standard of care in NAFLD. However, there is a striking lack of evidence to support the efficacy of lifestyle intervention to treat NAFLD in morbidly obese patients. Here, we aimed to assess the impact of lifestyle intervention on NAFLD in the morbidly obese in a real-world setting.

methods136 obese patients were included in an industry-independent, multiprofessional lifestyle intervention program with a lead-in phase of 12 weeks of formula diet and a total of 48 weeks intensive counselling. Body weight and markers of the metabolic syndrome were analyzed. Presence of NAFLD was screened for by use of non-invasive markers of fatty liver, non-alcoholic steatohepatitis and liver fibrosis.

resultsWeight loss goals (i.e. > 5% or > 10% of initial body weight, respectively, depending on baseline BMI) were achieved in 89.7% of subjects in the intention-to-treat analysis and 93.9% in the per-protocol analysis. This was associated with a pronounced improvement in serum ALT values. The percentage of subjects who fulfilled non-invasive criteria for fatty liver dropped from 95.2 to 54.8%. Risk of NASH improved and the number of patients at risk of liver fibrosis declined by 54.1%.

conclusionLifestyle intervention was associated with a marked improvement of serum ALT and an improvement of surrogate scores indicative of NAFLD and, importantly, advanced fibrosis, in a real-world cohort of morbidly obese patients.

Indexed as

Metabolic SyndromeNon-alcoholic Fatty Liver DiseaseObesity, MorbidBiomarkersHumansLife StyleLiverLiver CirrhosisBiomarkersLifestyle interventionLiver fibrosisMorbid obesityNAFLD

Identifiers

PMID35277756
PMCPMC9279260
OpenAlexW4221049727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.